I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $233.12M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| | ||||
AdipoGenix Inc. |
Boston |
11/17/03 |
ND |
AdipoGenix raised an undisclosed amount in a Series A financing led by Boston University's CTF Venture Fund and Medinnova Partners Inc. |
|
||||
Auxilium Pharmaceuticals Inc. |
Norristown, Pa. |
11/6/03 |
$43 |
Auxilium raised $43M in a Series D round of financing; new investors OrbiMed Advisors and BB Biotech joined previous investors SCP Private Equity Partners, Perseus-Soros BioPharmaceutical Fund, Lehman Brothers Private Equity, Schroder Ventures and CIP Capital |
|
||||
Chronogen Inc. |
Montreal |
11/26/03 |
C$17 |
Chronogen raised US$13.1M as part of an ongoing Series B financing; Desjardins Venture Capital led the round, which include Business Development Bank of Canada, CDP Capital-Technology Ventures and T2C2/Bio 2000 Ltd. Partnership |
|
||||
The Genetics Co. Inc. |
Zurich, Switzerland |
11/14/03 |
CHF14 (US$10.52) |
The total from the Series B round includes CHF5.5M from debt financing connected to earlier acquisitions; Nextech Venture and Novartis Venture Fund led the round, which included Najeti Capital, Heidelberg Innovations and individual investors |
|
||||
Glycart Biotechnology AG |
Zurich, Switzerland |
11/26/03 |
CHF18 (US$13.9) |
Glycart raised US$13.9M in its Series A financing; Global Life Science Ventures and Gilde Investment Management led the round, which included DVC Deutsche Venture Capital, ABN AMRO Capital, Quester Capital Management, BioMedinvest and Novartis Venture Fund |
|
||||
HepCgen Ltd. |
Southhampton, UK |
11/24/03 |
£1.6 (US$2.7) |
HepCgen raised US$2.7M in a second funding round; private and institutional investors participated in the investment |
|
||||
Intercell AG |
Vienna, Austria |
11/20/03 |
US$20 |
Intercell raised about US$20M in a second closing of a Series C round; the first closing in July totaled about US$34M, bringing the round's total to more than US$50M; MPM Capital led the second closing |
Lorantis Ltd. |
Cambridge, UK |
11/17/03 |
£25 (US$42.6) |
Lorantis raised US$42.6M in a Series C round led by funds advised by Apax Partners; also participating were existing investors Abingworth Management, JP Morgan Partners, Quester Capital Management, Schroder Ventures and funds managed by Fleming Family and Partners |
|
||||
NeuroMed Technologies |
Vancouver, British Columbia |
11/4 |
$32 |
MPM Capital led the Series C round; other investors were Discovery LP, TriFund Capital (VCC) Ltd. and Cogene Biotech Ventures, as well as previous investors GrowthWorks Capital, MDS Capital, BDC Venture Capital and the Royal Bank of Canada |
|
||||
Protein Forest Inc. |
Watertown, Mass. |
11/21 |
$19 |
Protein Forest raised $19M in a Series A round led by S.R. One LTD, Boston Millennia Partners, IDG Ventures, Novo A/S and private investors |
Purely Proteins Ltd. |
Cambridge, UK |
11/25 |
ND |
Purely Proteins said it completed its first funding round; Avlar BioVentures and Yorkshire Fund Managers invested in the round |
|
||||
Saegis Pharmaceuticals Inc. |
Half Moon Bay, Calif. |
11/17 |
$30 |
Saegis raised $30M in a Series B round led by Versant Ventures; other investors were Technology Partners, Sofinnova Ventures, Sofinnova Partners, Polaris Venture Partners and NeuroVentures |
|
||||
T-cellic A/S |
Horsholm, Denmark |
11/12 |
DKK40 (US$6.3) |
T-cellic raised the funds in its second financing round; Denmark's state pension fund joined exis- investors the Danish Investment Fund and Scandinavian Life Science Venture in the deal |
|
||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $3M | ||||
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
|
||||
AdipoGenix Inc.* |
Johnson & Johsnon |
ND |
Milestone payment |
Triggered by initial screening of J&J comp- ounds using AdipoGenix's assay platform (11/17) |
|
||||
Amrad Corp. Ltd. (Australia; ASX:AML) |
Merck Sharp & Dohme Pty. Ltd. (Australia) |
$3 |
Milestone payment |
The Merck & Co. Inc. subsidiary paid Amrad a preclinical milestone, the first from their alliance entered in June to develop drugs in the areas of respiratory diseases and cancer (11/20) |
|
||||
Jerini AG (Germany) |
Baxter Healthcare Corp. |
ND |
Milestone payment |
Jerini said it reached milestones in two deals by optimizing peptide lead molecules against two targets (11/4) |
|
||||
Lexicon Genetics Inc. (LEXG) |
Genentech Inc. |
ND |
Milestone payment |
Triggered by completion of first performance milestone under their December 2000 alliance to discover protein and antibody targets; details were not disclosed (11/10) |
|
||||
Medarex Inc. (MEDX) |
Amgen Inc. |
ND |
Milestone payment |
Medarex said it achieved a milestone in their 1999 collaboration but did not provide details (11/4) |
|
||||
Plexxikon Inc.* |
Genentech Inc. |
ND |
Milestone payment |
Triggered by Genentech's acceptance of a lead compound, a kinase inhibitor, for an oncology target under their May 2003 alliance (11/11) |
|
||||
The Speedel Group* (Switzerland) |
Novartis AG (Switzerland) |
ND |
Milestone payment |
Triggered by Novartis' decision to move the renin inhibitor Aliskiren into Phase III trials in hypertension (11/19) |
|
||||
Syrrx Inc.* |
PPD Inc. |
$25 |
Equity investment |
PPD purchased $25 in Syrrx convertible pre- ferred stock as part of a collaboration on dipeptidyl peptidase IV inhibitors for diabetes and other diseases (11/19) |
|
||||
| | ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
ND = Not disclosed. | ||||
ASX= Australian Stock Exchange. | ||||
To read more on related topics, click on one of the words below.